Hypothesis

Low molecular weight hyaluronan (LMW-HA) fragments generated by autophagic turnover of HAS2 act as extracellular danger signals that suppress autophagy through CD44‑TLR2/4‑mediated activation of mTORC1, establishing a vicious cycle that locks aged fibroblasts in a low‑autophagy, high‑ECM‑fragment state.

Mechanistic Model

1. Autophagy degrades HAS2 → reduces HA synthesis and produces LMW-HA fragments [1,2]
2. LMW-HA binds CD44 and TLR2/4 on the same fibroblast, triggering MyD88‑dependent NF‑κB and PI3K‑Akt signaling
3. Akt phosphorylates and activates mTORC1, which phosphorylates ULK1 at Ser757, inhibiting autophagy initiation [4]
4. mTORC1 also phosphorylates TFEB, retaining it in the cytosol and blocking lysosomal gene expression, further diminishing autophagic capacity
5. Reduced autophagy leads to accumulation of damaged HAS2 and other proteins, fostering more ECM breakdown and LMW-HA production
6. Collagen fragments suppress HAS2 transcription via ERK1/2‑ELK‑1 inhibition [3], lowering new HA synthesis and shifting the balance toward fragment‑driven signaling

Thus, the aged ECM becomes an active signaling hub that actively suppresses the very catabolic pathway meant to keep it in check.

Testable Predictions

• If LMW-HA fragments suppress autophagy, then exogenous addition of defined‑size LMW-HA (e.g., 200‑500 kDa) to young fibroblasts will decrease LC3‑II/I ratio and increase p62 after bafilomycin A1 treatment
• If CD44 or TLR4 signaling is required, then blocking antibodies or small‑molecule inhibitors (e.g., anti‑CD44, TAK‑242) will restore autophagic flux in the presence of LMW-HA
• If mTORC1 is the downstream effector, then rapamycin treatment will rescue autophagy even when LMW-HA fragments are present, without affecting fragment levels
• In aged human dermal fibroblasts, basal LMW-HA levels in the conditioned medium will be higher than in young cells, and siRNA knockdown of CD44 will increase autophagosome formation and reduce p62
• Conversely, overexpression of a non‑degradable HAS2 mutant (resistant to ATG9A‑mediated autophagy) will lower LMW‑HA production and increase autophagy, breaking the loop

Experimental Approach

• Cell models: primary human dermal fibroblasts from young (20‑30 yr) and aged (>65 yr) donors
• Treatments: recombinant LMW‑HA (defined size), collagen fragments, vehicle
• Readouts: Western blot for LC3‑II, p62, phospho‑ULK1 (Ser757), phospho‑S6K; immunofluorescence for LC3 puncta; qPCR for HAS2, CD44, TLR4; ELISA for HA fragments in media
• Interventions: anti‑CD44 antibody, TAK‑242 (TLR4 inhibitor), rapamycin, bafilomycin A1 for flux assay
• Controls: scrambled siRNA, IgG isotype, HA of high molecular weight (>2000 kDa) as negative control

Potential Outcomes and Interpretation

• Support: LMW‑HA reduces autophagy; blockade of CD44/TLR4 or mTOR inhibition restores flux; aged cells show higher basal LMW‑HA and rescue with CD44 knockdown
• Refute: LMW‑HA has no effect on autophagy markers, or blockade does not alter flux, suggesting other mechanisms dominate

This hypothesis directly addresses the reciprocal gap: ECM fragments are not just waste but active signals that shut down autophagy, providing a mechanistic basis for the observed decline in autophagic flux with age and offering clear, falsifiable experiments to test it.